^
Association details:
| Biomarker: | TMB-H + EGFR exon 19 deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
MA14.06 - High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
Published date:
08/18/2021
Excerpt:
...high TMB was independently associated with a shorter PFS in the overall population (hazard ratio [HR] = 2.64, p = 0.004), and associated with shorter OS in patients with exon 19 deletion (HR = 2.55, p = 0.041) compared with low TMB....High TMB was associated with unfavorable clinical outcome in patients with lung adenocarcinoma treated with EGFR-TKIs. Although further large-scaled studies are required, our data suggest that high TMB may be a predictive biomarker for adverse treatment outcomes...
